• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FDA 公开研讨会总结:推进抗菌药物开发的动物模型。

FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development.

机构信息

Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Oak Ridge Institute of Science and Education, Oak Ridge, Tennessee, USA.

出版信息

Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01983-20.

DOI:10.1128/AAC.01983-20
PMID:33106262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927847/
Abstract

The U.S. Food and Drug Administration (FDA) hosted a public workshop entitled "Advancing Animal Models for Antibacterial Drug Development" on 5 March 2020. The workshop mainly focused on models of pneumonia caused by and The program included discussions from academic investigators, industry, and U.S. government scientists. The potential use of mouse, rabbit, and pig models for antibacterial drug development was presented and discussed.

摘要

美国食品和药物管理局(FDA)于 2020 年 3 月 5 日举办了一场题为“推进抗菌药物开发的动物模型”的公开研讨会。该研讨会主要集中于 和 引起的肺炎模型。该计划包括来自学术研究人员、行业和美国政府科学家的讨论。还介绍和讨论了用于抗菌药物开发的小鼠、兔和猪模型的潜在用途。

相似文献

1
FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development.FDA 公开研讨会总结:推进抗菌药物开发的动物模型。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01983-20.
2
Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of , , and Complex.多中心评估新 Etest 梯度扩散法检测产 ESBL 肠杆菌科细菌对哌拉西林-他唑巴坦药敏试验的准确性
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01042-19.
3
Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii.将已获 FDA 批准的药物重新用于对抗耐多药鲍曼不动杆菌。
J Antimicrob Chemother. 2010 Dec;65(12):2598-601. doi: 10.1093/jac/dkq353. Epub 2010 Sep 22.
4
Model-Informed Drug Development and Review for Generic Products: Summary of FDA Public Workshop.基于模型的仿制药研发与审评:FDA 公开专题研讨会总结
Clin Pharmacol Ther. 2018 Jul;104(1):27-30. doi: 10.1002/cpt.1065. Epub 2018 Mar 30.
5
Advancing New Antibacterial Drug Development for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia.推进治疗医院获得性和呼吸机相关性细菌性肺炎的新型抗菌药物研发。
Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S37-8. doi: 10.1093/cid/ciw315.
6
Lysine-Based Small Molecule Sensitizes Rifampicin and Tetracycline against Multidrug-Resistant and .基于赖氨酸的小分子使利福平和四环素对多重耐药菌敏感。 (你提供的原文似乎不完整,最后的“and.”应补充完整内容才好准确翻译)
ACS Infect Dis. 2020 Jan 10;6(1):91-99. doi: 10.1021/acsinfecdis.9b00221. Epub 2019 Nov 19.
7
In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.重症监护病房患者中鲍曼不动杆菌和铜绿假单胞菌对碳青霉烯类药物的体外敏感性。
Adv Exp Med Biol. 2013;788:109-16. doi: 10.1007/978-94-007-6627-3_17.
8
In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.针对ESKAPE病原体对美国食品药品监督管理局(FDA)批准的文库进行体外筛选。
Curr Pharm Des. 2017;23(14):2147-2157. doi: 10.2174/1381612823666170209154745.
9
Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection.阳离子两亲性α-螺旋肽治疗耐碳青霉烯类鲍曼不动杆菌感染。
Biomaterials. 2012 Dec;33(34):8841-7. doi: 10.1016/j.biomaterials.2012.08.026. Epub 2012 Aug 25.
10
Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: in vitro and in vivo studies.采用中药半枝莲治疗广泛耐药鲍曼不动杆菌感染:体外和体内研究。
BMC Complement Altern Med. 2018 Mar 20;18(1):96. doi: 10.1186/s12906-018-2151-7.

引用本文的文献

1
efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing .在产OXA-48诱导的小鼠肺炎模型中,恩美他唑巴坦联合头孢吡肟的疗效
Microbiol Spectr. 2024 Oct 31;12(12):e0234524. doi: 10.1128/spectrum.02345-24.
2
Development of a new pneumonia rabbit model for the preclinical evaluation of future anti-infective strategies.开发一种用于未来抗感染策略临床前评估的新型肺炎兔模型。
Microbiol Spectr. 2024 Oct 18;12(12):e0157024. doi: 10.1128/spectrum.01570-24.
3
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus.基于模型的阿法比星对金黄色葡萄球菌活性的体外实验结果到体内实验的转化
J Antimicrob Chemother. 2024 Dec 2;79(12):3150-3159. doi: 10.1093/jac/dkae334.
4
Aerosolized delivery of ESKAPE pathogens for murine pneumonia models.雾化递送 ESKAPE 病原体用于建立小鼠肺炎模型。
Sci Rep. 2024 Jan 31;14(1):2558. doi: 10.1038/s41598-024-52958-9.
5
Animal Models in Regulatory Breakpoint Determination: Review of New Drug Applications of Approved Antibiotics from 2014-2022.监管断点确定中的动物模型:2014 - 2022年获批抗生素新药申请综述
J Pers Med. 2024 Jan 19;14(1):111. doi: 10.3390/jpm14010111.
6
Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.新型抗生素研发中的转化药代动力学/药效学——药物开发者视角
Antibiotics (Basel). 2024 Jan 11;13(1):72. doi: 10.3390/antibiotics13010072.
7
Development and validation of a rabbit model of non-ventilated pneumonia for preclinical drug development.开发和验证一种非通气性肺炎的兔模型,用于临床前药物开发。
Front Cell Infect Microbiol. 2023 Dec 11;13:1297281. doi: 10.3389/fcimb.2023.1297281. eCollection 2023.
8
Small-Molecule Antibiotic Drug Development: Need and Challenges.小分子抗生素药物研发:需求与挑战。
ACS Infect Dis. 2023 Nov 10;9(11):2062-2071. doi: 10.1021/acsinfecdis.3c00189. Epub 2023 Oct 11.
9
Monoclonal antibodies neutralizing alpha-hemolysin, bicomponent leukocidins, and clumping factor A protected against -induced acute circulatory failure in a mechanically ventilated rabbit model of hyperdynamic septic shock.抗α-溶血素、双组分白细胞毒素和凝聚因子 A 的单克隆抗体可预防机械通气兔高动力型感染性休克模型中诱导的急性循环衰竭。
Front Immunol. 2023 Sep 15;14:1260627. doi: 10.3389/fimmu.2023.1260627. eCollection 2023.
10
Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.对抗抗生素耐药性——寻找新抗菌药物的策略和(临床前)研发。
EMBO Rep. 2023 Jan 9;24(1):e56033. doi: 10.15252/embr.202256033. Epub 2022 Dec 19.

本文引用的文献

1
Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial Pneumonia.评估用于治疗细菌性肺炎的新药临床试验中细菌性肺炎动物模型。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02242-19.
2
Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.头孢他啶-阿维巴坦治疗持续中性粒细胞减少兔产碳青霉烯酶肺炎克雷伯菌肺炎的药代动力学和疗效。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02157-19.
3
Natural history of Acinetobacter baumannii infection in mice.鲍曼不动杆菌感染小鼠的自然史。
PLoS One. 2019 Jul 18;14(7):e0219824. doi: 10.1371/journal.pone.0219824. eCollection 2019.
4
Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.头孢洛扎他唑巴坦治疗持续性中性粒细胞减少兔实验性铜绿假单胞菌肺炎:对具有遗传耐药机制的菌株的影响。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00344-19. Print 2019 Sep.
5
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia.呼吸机相关性和医院获得性细菌性肺炎的小鼠口咽误吸模型
J Vis Exp. 2018 Jun 28(136):57672. doi: 10.3791/57672.
6
Development and evaluation of murine lung-specific disease models for Pseudomonas aeruginosa applicable to therapeutic testing.适用于治疗测试的铜绿假单胞菌小鼠肺特异性疾病模型的开发与评估。
Pathog Dis. 2015 Jul;73(5). doi: 10.1093/femspd/ftv025. Epub 2015 Apr 9.